Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, Nixon A, Turnbull B, Garmey EG, Gunnarsson O, Waliki M, Ciconte J, Jayaraman L, Senderowicz A, Tellez AB, Hennessy M, Piscitelli A, Vaughn D, Smith A, Haas NB. Keefe SM, et al. Among authors: eliasof s. Ann Oncol. 2016 Aug;27(8):1579-85. doi: 10.1093/annonc/mdw188. Epub 2016 Jun 8. Ann Oncol. 2016. PMID: 27457310 Free PMC article. Clinical Trial.
CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
Conley SJ, Baker TL, Burnett JP, Theisen RL, Lazarus D, Peters CG, Clouthier SG, Eliasof S, Wicha MS. Conley SJ, et al. Among authors: eliasof s. Breast Cancer Res Treat. 2015 Apr;150(3):559-67. doi: 10.1007/s10549-015-3349-8. Epub 2015 Apr 2. Breast Cancer Res Treat. 2015. PMID: 25833208
Discovery of a Novel Cabazitaxel Nanoparticle-Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects Using a β-Cyclodextrin-PEG Copolymer Based Delivery Platform.
Metcalf CA 3rd, Svenson S, Hwang J, Tripathi S, Gangal G, Kabir S, Lazarus D, Cole R, Sweryda-Krawiec B, Shum P, Brown D, Case RI, van der Poll D, Rohde E, Harlfinger S, Teng CH, Eliasof S. Metcalf CA 3rd, et al. Among authors: eliasof s. J Med Chem. 2019 Nov 14;62(21):9541-9559. doi: 10.1021/acs.jmedchem.9b00892. Epub 2019 Oct 24. J Med Chem. 2019. PMID: 31593466
25 results